Continuation Study for Latozinemab

ClinicalTrials.gov ID: NCT06111014

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06111014. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Continuation Study of Latozinemab in Participants With Neurodegenerative Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study

Study identification

NCT ID: NCT06111014
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Alector Inc.; Industry
Enrollment: 17 participants

Conditions and interventions

Conditions

Neurodegenerative Diseases

Interventions

Latozinemab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 8, 2023 (Actual)
Primary completion: Sep 1, 2025 (Actual)
Completion: Jan 7, 2026 (Actual)
Last update posted: Jan 21, 2026

2023 – 2026

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
Dignity Health - Arizona	Phoenix	Arizona	85013	—
Mayo Comprehensive Cancer Center - PPDS	Rochester	Minnesota	55905	—
Irving Institute for Clinical and Translational Research	New York	New York	10032	—
University of Cincinnati Gardner Neuroscience Institute	Cincinnati	Ohio	45219	—
University of Pennsylvania	Philadelphia	Pennsylvania	19104	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06111014, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 21, 2026 · Synced Nov 14, 2026